Sanofi strong in 1Q despite diabetes slump as Brandicourt starts strategic review
This article was originally published in Scrip
Sanofi's new CEO Olivier Brandicourt was able to report a strong set of first quarter results just a few weeks after taking the helm, which hardly seems fair to ousted CEO Chris Viehbacher. Sanofi's first quarter sales increased by 2% at constant exchange rates to €8.8bn (12% on a reported basis owing to the weak euro), which was above analysts' expectations. However, its diabetes business is still a major concern.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.